Estimated impact of long‐acting injectable PrEP in South Africa: a model comparison analysis

作者：Sarah E. Stansfield, Mia Moore, Lise Jamieson, Gesine Meyer‐Rath, Leigh F. Johnson, David Kaftan, Anna Bershteyn, Jennifer S. Smith, Valentina Cambiano, Loveleen Bansi‐Matharu, Andrew Phillips, Jesse Heitner, Ruanne V. Barnabas, Brett Hanscom, Deborah Donnell, Marie‐Claude Boily, Dobromir Dimitrov · 发表于：Journal of the International AIDS Society · 年份：2025 · DOI：10.1002/jia2.26453 · 被引用次数：4 · 研究领域：HIV/AIDS Research and Interventions、HIV/AIDS drug development and treatment、HIV, Drug Use, Sexual Risk

INTRODUCTION: Long-acting injectable cabotegravir (CAB-LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in two clinical trials. This analysis projects the impact of expanding PrEP coverage with CAB-LA in South Africa between 2022 and 2042. METHODS: Three independently calibrated models of HIV transmission in South Africa (Synthesis, EMOD-HIV, Thembisa) projected HIV acquisitions and effective coverage (average PrEP coverage across exposure groups, weighted by HIV incidence in the absence of PrEP in each group) over 20 years under multiple scenarios of PrEP expansion compared to no PrEP expansion. PrEP expansion scenarios differed in targeted overall coverage, speed of expansion, coverage of high-exposure groups, and relative coverage of women and men. RESULTS: Achieving 5% PrEP coverage with CAB-LA by 2032 prioritizing high-exposure groups resulted in 49% (Synthesis), 18% (EMOD-HIV), and 8% (Thembisa) effective coverage and averted a median of 43%, 29% and 10% of new HIV acquisitions, respectively. Similar expansion with TDF/FTC resulted in lower impact by 19 percentage points (pp), 18pp and 3pp, respectively. Increasing CAB-LA coverage to 15% led to an additional 7pp, 12pp and 16pp, respectively, of HIV acquisitions averted. Achieving 5% CAB-LA coverage expanding to women only resulted in a lower impact by 16pp (Synthesis) and 13pp (EMOD-HIV), and a higher impact...